[A21-132] Enzalutamide (prostate cancer) - Addendum to Commission A21-77
Last updated 19.11.2021
Project no.:
A21-132
Commission:
Commission awarded on 12.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Result of dossier assessment:
Unchanged after addendum:
Hint of non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-77 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.